Research findings from Sylvester Comprehensive Cancer Center will be presented at ASCO 2025 May 30-June3. This tip sheet includes titles for nearly 70 sessions and presentations in which Sylvester researchers are involved.
Two years after receiving an investigational gene therapy as part of a clinical trial co-led by UCLA鈥檚 Dr. Donald Kohn, nine children born with a life-threatening immune disorder are living free of disease symptoms.
Researchers from UC San Diego found that Mindfulness-Oriented Recovery Enhancement (MORE) can help rewire the brain鈥檚 response to natural healthy pleasure, leading to reduced opioid cravings. The findings suggest that MORE could be a promising tool in the fight against opioid use disorder.
Every year, some mothers die after giving birth due to heart problems, and many of these deaths could be prevented. The ability to screen for heart weakness before pregnancy could play a crucial role in identifying women who may need additional care to improve pregnancy outcomes.
Black and Hispanic children with high-risk neuroblastoma experience worse survival outcomes than their white peers, even when treated in frontline clinical trials, according to a study led by a UT Southwestern Medical Center researcher. Published in JAMA Network Open, the study is believed to be the first to comprehensively evaluate survival by race and ethnicity in a national cohort of children with high-risk neuroblastoma enrolled in clinical trials.
鈥� Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress for CAR T cell therapy in solid tumors 鈥� One patient experienced a complete response, and one patient had a partial response 鈥� This type of cancer has limited treatment options, and most patients have a poor prognosis of six months or less 鈥� AIC100 is a CAR T cell therapy that targets the ICAM-1 protein on tumor cells
The Society for Clinical Trials (SCT) is pleased to announce that the prestigious David Sackett Trial of the Year Award will be presented to 鈥淏linatumomab in Childhood Standard-Risk B-Cell Acute Lymphoblastic Leukemia.鈥�
Today, Penn Medicine celebrated the groundbreaking of the Roberts Proton Therapy Center at Penn Presbyterian Medical Center in University City, which is expected to open for patient care in late 2027.
鈥� RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors 鈥� Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors 鈥� This class of drugs is important because many solid tumor patients with microsatellite instability (MSI) do not benefit from currently approved immunotherapies 鈥� Encouraging early results in this first-in-human trial prompted additional trial cohorts to optimize recommended dose for future clinical development
UCLA researchers demonstrated that a novel topical BRAF inhibitor gel called LUT014 significantly reduces the severity of an acne-like rash, a common and painful side effect experienced by patients undergoing anti-EGFR therapies for colorectal cancer.
路 LUT014, a topical BRAF inhibitor made by Lutris Pharma, is the first agent to treat the cause of the rash without interfering with the treatment itself 路 Over two-thirds of patients had successful treatment with the higher dose of LUT014 compared to one-third with placebo
20240208171546.png&width=400&height=400)
New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), demonstrate how immunotherapy alone can allow people with MMRd cancers to avoid surgery and preserve their quality of life. The results, presented at the 2025 American Association of Cancer Research (AACR) Annual Meeting and published simultaneously in The New England Journal of Medicine (NEJM), found that 80 percent of patients did not require surgery, radiation, or chemotherapy after six months of treatment with immunotherapy alone.
鈥� Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations 鈥� Combination demonstrated complete responses and partial responses in different cancer types, including those beyond the currently approved indications for these therapies
An international phase 3 clinical trial led by Washington University School of Medicine in St. Louis and Dana-Farber Brigham Cancer Center shows that patients with certain locally advanced head and neck cancers benefited from the addition of the immunotherapy drug pembrolizumab (brand name Keytruda) to standard-of-care therapy. Patients who received pembrolizumab saw greater tumor shrinkage prior to surgery and, on average, survived cancer-free almost two years longer than did patients who only received standard-of-care therapy.
New research has shown that hypertensive individuals who maintain optimal control of several key health risk factors鈥攕uch as blood pressure, cholesterol, and lifestyle behaviors鈥攃an significantly reduce their risk of dying prematurely. The study found that with each additional risk factor brought under control, the risk of death from cancer, cardiovascular disease, and other causes dropped substantially. Most importantly, those who achieved high levels of joint risk factor control had no greater risk of early death than people without hypertension. This suggests that a comprehensive, multi-pronged approach to managing hypertension could effectively eliminate the excess mortality risk associated with the condition.
Dry eye disease (DED) is a multifactorial disorder that disturbs ocular surface equilibrium, considerably diminishing quality of life. Present therapies only offer symptomatic alleviation. Stem cell treatment, especially mesenchymal stem ce
Patients with advanced non-small cell lung cancer (NSCLC) are often treated with immunotherapy drugs known as checkpoint inhibitors, which are designed to strengthen the immune system鈥檚 ability to kill cancer cells 鈥� but these drugs do not produce a lasting response in most patients with this cancer type.
Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in three minisymposia abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025. Findings include a personalized vaccine combination therapy for colorectal cancer, the use of radiotherapy to avoid the toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancreatic cancer.
Researchers with UC San Diego Health identify a potential new treatment for uncontrolled high blood pressure.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right